Home  |  Contact

UniProtKB/Swiss-Prot O15270: Variant p.Ile504Phe

Serine palmitoyltransferase 2
Gene: SPTLC2
Variant information

Variant position:  504
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Isoleucine (I) to Phenylalanine (F) at position 504 (I504F, p.Ile504Phe).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and hydrophobic (I) to large size and aromatic (F)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In HSAN1C; partial loss of normal activity as measured by reduced formation of sphinganine; affects enzymatic affinity resulting in the accumulation of the alternative metabolite 1-deoxy-sphinganine.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  504
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  562
The length of the canonical sequence.

Location on the sequence:   REMLKRNIGVVVVGFPATPI  I ESRARFCLSAAHTKEILDTA
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         REMLKRNIGVVVVGFPATPIIESRARFCLSAAHTKEILDTA

Mouse                         REMLKRNIGVVVVGFPATPIIESRARFCLSAAHTKEILDTA

Rat                           REMLKRNIGVVVVGFPATPIIESRARFCLSAAHTKEILDTA

Caenorhabditis elegans        REMLARNIGCVVVSFPATHMTEGRVRFCISAAHTKEQLDEV

Slime mold                    RLCLEKHIAVVVVGYPATPLTEPRTRFCISASHTIEDLDWA

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 562 Serine palmitoyltransferase 2


Literature citations

Mutations in the SPTLC2 subunit of serine palmitoyltransferase cause hereditary sensory and autonomic neuropathy type I.
Rotthier A.; Auer-Grumbach M.; Janssens K.; Baets J.; Penno A.; Almeida-Souza L.; Van Hoof K.; Jacobs A.; De Vriendt E.; Schlotter-Weigel B.; Loscher W.; Vondracek P.; Seeman P.; De Jonghe P.; Van Dijck P.; Jordanova A.; Hornemann T.; Timmerman V.;
Am. J. Hum. Genet. 87:513-522(2010)
Cited for: FUNCTION; VARIANTS HSAN1C MET-359; VAL-382 AND PHE-504; CHARACTERIZATION OF VARIANTS HSAN1C MET-359; VAL-382 AND PHE-504;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.